Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human LMTK2 Antibodies:
anti-Mouse (Murine) LMTK2 Antibodies:
anti-Rat (Rattus) LMTK2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal LMTK2 Primary Antibody for ICC, IF - ABIN4331265
Shah, Bradbury: Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy. in Oncotarget 2015
Human Polyclonal LMTK2 Primary Antibody for ELISA, WB - ABIN4230127
Zheng, Hsing, Sun, Chu, Yu, Li, Gao, Kim, Isaacs, Shen, Gao, Hoover, Xu: Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. in The Prostate 2010
both BIM (show BCL2L11 Antibodies) and BCL2 (show BCL2 Antibodies) proteins are regulated by LMTK2 in a GSK3beta (show GSK3b Antibodies)- and PP1A (show PPP1CA Antibodies)-dependent manner.
Mutation of the di-acidic export motif led to endoplasmic reticulum retention of LMTK2, and an increase in protein half-life.
Lemur Tyrosine Kinase-2 (LMTK2), negatively regulates androgen-dependent and androgen-independent prostate cancer cell proliferation. In addition, LMTK2 also negatively regulates the androgen receptor (show AR Antibodies) transcriptional activity.
Data indicate that Lemur tyrosine kinase 2 (LMTK2) localizes at the plasma membrane and co-immunoprecipitates with cystic fibrosis transmembrane conductance regulator (CFTR (show CFTR Antibodies)) in airway epithelial cells.
The results indicate that lemur tyrosine kinase 2 is an integral membrane protein in which both the amino and carboxyl termini are exposed to the cytoplasm. Moreover, this topology places the kinase active site within the cytoplasm.
We describe a new signalling pathway within the nervous system that links cdk5 (show CDK5 Antibodies)/p35 (show ANXA1 Antibodies) with phosphatase-1C and which has implications for a number of neuronal functions and neuronal dysfunction
Low LMTK2 expression is associated with the development of prostate cancer.
Data show that downregulation of myosin VI (show MYO6 Antibodies) expression results in a significant reduction in PSA (show PLAG1 Antibodies) and VEGF (show VEGFA Antibodies) secretion in LNCaP cells, and the intracellular targeting seems to involve myosin VI (show MYO6 Antibodies)-interacting proteins, GIPC (show GIPC1 Antibodies) and LMTK2 and Dab2 (show DAB2 Antibodies).
KPI-2 is a kinase with sites to associate with PP1C and Inh2 to form a regulatory complex that is localized to membranes
Cprk is expressed in a number of tissues but is enriched in brain and muscle; Cprk displays catalytic activity in kinase assays and is itself phosphorylated by cdk5 (show CDK5 Antibodies)/p35 (show ANXA1 Antibodies); Cdk5 (show CDK5 Antibodies)/p35 (show ANXA1 Antibodies) inhibits cprk activity
The protein encoded by this gene belongs to the protein kinase superfamily and the protein tyrosine kinase family. It contains N-terminal transmembrane helices and a long C-terminal cytoplasmic tail with serine/threonine/tyrosine kinase activity. This protein interacts with several other proteins, such as Inhibitor-2 (Inh2), protein phosphatase-1 (PP1C), p35, and myosin VI. It phosporylates other proteins, and is itself also phosporylated when interacting with cyclin-dependent kinase 5 (cdk5)/p35 complex. This protein involves in nerve growth factor (NGF)-TrkA signalling, and also plays a critical role in endosomal membrane trafficking. Mouse studies suggested an essential role of this protein in spermatogenesis.
, apoptosis-associated tyrosine kinase 2
, brain-enriched kinase
, cyclin-dependent kinase 5/p35-regulated kinase
, kinase phosphatase inhibitor 2
, kinase/phosphatase/inhibitor 2
, serine/threonine-protein kinase KPI-2
, serine/threonine-protein kinase LMTK2